Get the Stockscreener App
3.87
1.31%
0.05
Pre-market:
3.88
0.010
+0.26%
Aclaris Therapeutics Inc stock is traded at $3.87, with a volume of 1.20M.
It is up +1.31% in the last 24 hours and up +27.72% over the past month.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.
See More
Previous Close:
$3.82
Open:
$3.84
24h Volume:
1.20M
Relative Volume:
0.66
Market Cap:
$419.30M
Revenue:
$27.08M
Net Income/Loss:
$-37.00M
P/E Ratio:
-7.4423
EPS:
-0.52
Net Cash Flow:
$-18.46M
1W Performance:
-12.64%
1M Performance:
+27.72%
6M Performance:
+127.65%
1Y Performance:
+57.96%
1-Day Range:
$3.7801
$3.9899
1-Week Range:
$3.705
$4.84
52-Week Range:
$1.05
$4.89
Aclaris Therapeutics Inc Stock (ACRS) Company Profile
Name
Aclaris Therapeutics Inc
Sector
Industry
Phone
484-324-7933
Address
701 LEE ROAD, WAYNE, PA
Compare ACRS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ACRS
Aclaris Therapeutics Inc
|
3.87 | 413.88M | 27.08M | -37.00M | -18.46M | -0.52 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.17 | 120.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
771.25 | 80.15B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
864.42 | 51.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
354.75 | 47.74B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
336.16 | 37.38B | 4.98B | 69.59M | 525.67M | 0.5197 |
Aclaris Therapeutics Inc Stock (ACRS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-10-25 | Resumed | Piper Sandler | Overweight |
| May-28-25 | Initiated | Wedbush | Outperform |
| Mar-18-25 | Resumed | Cantor Fitzgerald | Overweight |
| Dec-23-24 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Nov-20-24 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Nov-19-24 | Upgrade | BTIG Research | Neutral → Buy |
| Nov-19-24 | Upgrade | Jefferies | Hold → Buy |
| Nov-19-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Nov-18-24 | Upgrade | Piper Sandler | Neutral → Overweight |
| Jan-22-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Nov-13-23 | Downgrade | William Blair | Outperform → Mkt Perform |
| Oct-03-23 | Initiated | Evercore ISI | Outperform |
| Dec-14-22 | Initiated | Stifel | Buy |
| Dec-01-22 | Initiated | Goldman | Buy |
| Oct-06-22 | Initiated | BTIG Research | Buy |
| Jul-23-21 | Resumed | Jefferies | Buy |
| Jun-15-21 | Initiated | Piper Sandler | Overweight |
| Apr-21-21 | Initiated | H.C. Wainwright | Buy |
| Oct-22-19 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Sep-06-19 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Jun-27-19 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| May-06-19 | Initiated | SVB Leerink | Outperform |
| Mar-28-18 | Resumed | Leerink Partners | Outperform |
| Feb-09-18 | Initiated | Guggenheim | Buy |
| Jun-16-17 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-29-16 | Initiated | Leerink Partners | Outperform |
| Sep-30-16 | Initiated | JMP Securities | Mkt Outperform |
| Jun-10-16 | Initiated | Guggenheim | Buy |
| Nov-02-15 | Initiated | Citigroup | Buy |
| Nov-02-15 | Initiated | Jefferies | Buy |
View All
Aclaris Therapeutics Inc Stock (ACRS) Latest News
Aclaris reports positive preclinical results for hair loss drug By Investing.com - Investing.com Canada
Aclaris Hair Loss Drug Shows Faster Results Than Pfizer's Drug - Benzinga
Aclaris reports positive preclinical results for hair loss drug - Investing.com
Aclaris Therapeutics' ATI-2138 Shows Superior Efficacy Against Ritlecitinib in Alopecia Universalis Model - Quiver Quantitative
Aclaris oral compound restores 93% hair in severe alopecia mice - Stock Titan
Investor Alert: Common Warts Market Set for Rapid Growth – DelveInsight | Nielsen BioSciences, Verrica Pharmaceutical, Kino Pharma, Iwaki Pharma, Aclaris Therapeutics - Barchart.com
Aclaris Therapeutics, Inc.'s (NASDAQ:ACRS) high institutional ownership speaks for itself as stock continues to impress, up 72% over last week - simplywall.st
Market Rankings: What is Aclaris Therapeutics Incs book value per shareProfit Target & High Return Trade Opportunity Guides - baoquankhu1.vn
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Receives Average Recommendation of “Moderate Buy” from Analysts - Defense World
Aclaris Therapeutics (NASDAQ:ACRS) nasdaq top 100 Clinical Pipeline - Kalkine Media
Aclaris pushes new antibody into skin disease trial, eyes asthma next - MSN
Aclaris Therapeutics Launches Phase 2 Trial for Promising Atopic Dermatitis Treatment - MSN
Aclaris Therapeutics (NASDAQ:ACRS) Receives Buy Rating from HC Wainwright - MarketBeat
ACRS: Analyst Maintains Buy Rating and $16 Price Target | ACRS S - GuruFocus
There's Reason For Concern Over Aclaris Therapeutics, Inc.'s (NASDAQ:ACRS) Massive 41% Price Jump - 富途牛牛
Income Plays: What are the future prospects of Aclaris Therapeutics IncWeekly Profit Analysis & Real-Time Stock Entry Alerts - baoquankhu1.vn
Aclaris Therapeutics (NASDAQ:ACRS) Reaches New 1-Year HighHere's What Happened - MarketBeat
Aclaris Pushes New Antibody Into Skin Disease Trial, Eyes Asthma Next - mychesco.com
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
Can Aclaris Therapeutics Inc. (8AT) stock withstand sector downturnsMarket Activity Report & High Accuracy Investment Entry Signals - bollywoodhelpline.com
Aclaris Therapeutics initiates Phase 1b proof-of-concept trial of ATI-052 - Yahoo Finance
Aclaris begins phase 1b trial of ATI-052 for atopic dermatitis - Investing.com Nigeria
Aclaris begins phase 1b trial of ATI-052 for atopic dermatitis By Investing.com - Investing.com South Africa
Aclaris Therapeutics Initiates Phase 1b Proof-of-Concept Trial in Atopic Dermatitis (AD) with Its Novel Bispecific Antibody ATI-052 - The Manila Times
Aclaris Therapeutics, Inc Updates Corporate Overview Presentation - TradingView
Aclaris Therapeutics Initiates Phase 1b Proof-of-Concept - GlobeNewswire
Palvella’s QTORIN Pipeline Targets a Breakout Moment in Rare Skin Care - MyChesCo
Why Aclaris Therapeutics Inc. stock could rally in 2025Entry Point & Precise Trade Entry Recommendations - Улправда
Financial Comparison: Aclaris Therapeutics (NASDAQ:ACRS) and Jaguar Animal Health (NASDAQ:JAGX) - Defense World
Will Aclaris Therapeutics Inc. stock benefit from green energy trendsJuly 2025 Earnings & Daily Profit Focused Screening - Улправда
Early trial data puts Aclaris’ ATI-052 on fast track toward bigger bets - MSN
What valuation multiples suggest for Aclaris Therapeutics Inc. stockWeekly Stock Analysis & Long-Term Growth Plans - Улправда
Is Aclaris Therapeutics Inc. stock affected by interest rate hikesTrade Exit Report & Precise Swing Trade Alerts - Улправда
How Aclaris Therapeutics Inc. stock benefits from strong dollar2025 Breakouts & Breakdowns & AI Powered Trade Plan Recommendations - ulpravda.ru
Market Recap: Can Aclaris Therapeutics Inc. (8AT) stock withstand sector downturnsJuly 2025 Pullbacks & Intraday High Probability Alerts - Улправда
Is Aclaris Therapeutics Inc. stock attractive for passive investorsBond Market & Free AI Powered Buy and Sell Recommendations - ulpravda.ru
Why analysts upgrade Aclaris Therapeutics Inc. stockMarket Sentiment Summary & Reliable Momentum Entry Alerts - Улправда
Aclaris joins Nasdaq biotech index, marking milestone for clinical-stage firm - MSN
Early Trial Data Puts Aclaris’ ATI-052 on Fast Track Toward Bigger Bets - mychesco.com
The week in pharma: action, reaction and insight – week to January 19, 2024 - The Pharma Letter
Aclaris Therapeutics Reports Positive Interim Phase 1a ATI-052 Data, Speeds Up Development Plans - Defense World
Jefferies reiterates Buy rating on Aclaris Therapeutics stock at $7 price target By Investing.com - Investing.com South Africa
Jefferies reiterates Buy rating on Aclaris Therapeutics stock at $7 price target - Investing.com Nigeria
Aclaris Therapeutics Reports Positive Phase 1a Data For ATI-052 - Nasdaq
Aclaris advances ATI-052 after positive Phase 1a results - TipRanks
Aclaris reports positive results for anti-inflammatory drug ATI-052 By Investing.com - Investing.com South Africa
Aclaris Therapeutics Announces Positive Interim Results from Phase 1a Trial of ATI-052 - TradingView — Track All Markets
ACRS: ATI-052 showed best-in-class potential in phase 1a, enabling rapid advancement to phase 1b trials - TradingView — Track All Markets
Aclaris Therapeutics Reports Positive Interim Results for ATI-052 Phase 1a Trials and Outlines Future Development Plans - Quiver Quantitative
Aclaris Therapeutics Inc Stock (ACRS) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.09%
0.48%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):